Shenzhen Yahuilong Biotechnology Co., Ltd. (hereinafter referred to as the "Company" or "Yahuilong") recently signed the "National Key R&D Program Project Task Book" with the Ministry of Science and Technology of the People's Republic of China, and took the lead in undertaking the research and development of high-performance immunofield rapid detection system (hereinafter referred to as the "project") of the "14th Five-Year Plan" National Key R&D Program "Diagnosis and Treatment Equipment and Biomedical Materials". The relevant situation is hereby announced as follows:
First, the basic situation of the project
1. Project name (number): R&D of high-performance immunofield rapid detection system (2023YFC2413000).
2. Special projects: diagnosis and treatment equipment and biomedical materials.
3. Lead unit: Shenzhen Yahuilong Biotechnology Co., Ltd
4. Project Leader: Zhou Zhou.
5. Project implementation period: November 2023 - October 2027.
6. The total project fund: 52 million yuan, of which 12 million yuan is the first financial fund.
7. Other participating units: Fuwai Hospital, Chinese Academy of Medical Sciences, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Shandong University, Shandong Alkeda Biotechnology, Shandong Normal University, Shanghai Jiao Tong University, Peking University First Hospital, University of Science and Technology Beijing, Chongqing University.
8. Project Introduction: Cardiovascular and cerebrovascular diseases are the diseases with the highest mortality rate among Chinese residents, and high-performance immunization on-site rapid detection is a necessary means for clinical diagnosis and treatment of cardiovascular and cerebrovascular emergencies. The on-site rapid immunoassay technology based on microfluidics is highly integrated with the sample pretreatment and detection process, which can accurately, quickly and conveniently diagnose cardiovascular and cerebrovascular diseases, and has become a research hotspot in this field. The existing detection technologies still cannot meet the above clinical needs in terms of anti-interference, sensitivity, precision, detection time, and quality control system. In response to the above-mentioned challenges, Yahuilong took the lead in undertaking this project, and jointly established a multidisciplinary team of industry, academia, research and medical testing with research institutions such as hospitals affiliated to the National Health Commission, the Chinese Academy of Sciences and universities, focusing on the development and industrialization of high-performance immunization on-site rapid detection equipment and supporting reagents, and improving the overall medical service capacity of existing critical and critical diseases.
In response to the clinical needs of accurate and quantitative on-site rapid immunoassays, this project builds and optimizes a high-performance on-site immunoassay rapid detection system through key technical research, and completes the research and development of a variety of cardiovascular and cerebrovascular marker detection reagents, and is committed to solving the problems of on-site whole blood detection interference, low sensitivity of trace detection, and time-consuming detection links.
2. Impact on the company
In 2014, the "Plan for Deepening the Management Reform of the Fiscal Science and Technology Plan (Special, etc.) (Guo Fa 2014 No. 64)" was issued, and the national key research and development plan was newly established, focusing on funding major social welfare research related to the long-term evolution of the national economy and people's livelihood, and the strategic, basic and forward-looking major scientific issues, major common key technologies and product research and development related to the core competitiveness of the industry, the overall independent innovation ability and the research and development of major common key technologies and products, as well as major international scientific and technological cooperation, etc., to strengthen cross-departmental and Cross-industry and cross-regional R&D layout and collaborative innovation provide continuous support and guidance for the main areas of national economic and social development. The key special project is the carrier for the organization and implementation of the national key R&D plan, focusing on major national strategic tasks, goal-oriented, and carrying out the whole chain of innovative design and integrated organization and implementation from basic frontiers, major common key technologies to application demonstrations.
The approval of this project is the country's recognition of Yahuilong's R&D and application capabilities in the field of biomedical testing, which reflects the company's advantages in technological innovation strength, organizational management capabilities and talent accumulation, which is conducive to the company to further strengthen the research and development of cutting-edge biological detection technology of microfluidics, and is of great significance for comprehensively improving the diagnosis and treatment capabilities of acute and critical cardiovascular diseases. The company will also take the implementation of this project as an opportunity to actively respond to the major strategic needs of the country, continue to increase R&D investment, and launch in vitro diagnostic products that are more in line with the needs of clinical use.
The total funding of this project is 52 million yuan, of which 12 million yuan is the first financial fund, which is enjoyed by the participating units in accordance with the research topic, of which the company should enjoy the first financial fund of 1.8 million yuan will be received in installments, and the company will deal with it in accordance with the relevant provisions of the accounting standards. In addition, the company needs to raise 28 million yuan by itself, and the company will invest it in installments with self-raised funds according to the progress of the project, which will not have a significant impact on the company's near-term financial indicators.
3. Risk Warning
1. The implementation time of this project is long, and there may be risks in technology, policy, organization, implementation and management in the process of project promotion, and there is a certain degree of uncertainty.
2 The project is affected by the development of the industry, national policies, acceptance of new products, etc., and there are uncertainties in the market application and promotion, product sales and profit contribution of the products developed by the project. Investors are advised to invest rationally and pay attention to investment risks.
The announcement is hereby made. Shenzhen Yahuilong Biotechnology Co., Ltd. ***
Board of directors. December 14, 2023.